Navigation Links
Actavis Receives Approval of Levetiracetam Oral Solution in the U.S.
Date:1/21/2009

MORRISTOWN, N.J., Jan. 21 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Levetiracetam Oral Solution. Distribution of the product has commenced.

Levetiracetam Oral Solution is available in the 100mg/mL strength and is the generic equivalent of Keppra(R) Oral Solution by UCB, Incorporated. Levetiracetam Oral Solution is used in the treatment of partial onset seizures in adults and children with epilepsy. Annual U.S. sales of Keppra(R) Oral Solution were US$95.9 million for the 12 months ending September 2008 according to IMS Health data.

Commenting on the new approval, Doug Boothe, CEO of Actavis in the United States said:

"The approval of Levetiracetam Oral Solution demonstrates our continuing commitment to introduce new generic products to the marketplace, as well as highlights our expertise in developing and manufacturing a wide range of dosage forms. Actavis' drive to be a leader in generic pharmaceuticals is supported by one of the largest product development pipelines in the industry. "

About Actavis

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 40 countries, with 11,000 employees. The United States is the company's single largest market. Actavis' U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.

More information about Actavis in the United States can be found at www.actavis.us.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Actavis Receives Approval of Generic Wellbutrin XL(R) 150mg in the U.S.
2. Actavis Receives Approval of Generic Wellbutrin XL(R) 300mg in the U.S.
3. Harvard Business School Publishes a Case Study on Robert Wessman and Actavis
4. Actavis Extends Portfolio With Four New Products in the U.S.
5. Actavis Confirms its Patent Challenge of Kings Avinza(R)
6. Actavis Launches Amlodipine Tablets in the U.S.
7. Actavis Launches Carvedilol Tablets in the U.S.
8. Horphag Research Receives 2008 Frost & Sullivan North American Health Ingredients Excellence In Research Award
9. Samplify Systems Receives Top Honors From Electronic Products and EDN Magazines
10. Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance
11. Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... (PRWEB) , ... March 30, 2017 , ... Although many ... concerns, equally as many are wary of baring their skin for other reasons, including ... at West Dermatology can help get the skin prepared for the summer weather and ...
(Date:3/30/2017)... Philadelphia, PA (PRWEB) , ... March 30, 2017 ... ... Wharton School is expanding its educational offerings of corporate finance programs to address ... a new program, will help executives increase their knowledge of sophisticated corporate finance ...
(Date:3/30/2017)... , ... March 30, 2017 , ... ... the Academy of Nutrition and Dietetics (AND), will join nonprofit Seafood Nutrition Partnership ... America,” a live webinar designed to help nutrition educators and students inform consumers ...
(Date:3/29/2017)... ... 29, 2017 , ... During the last week of March, Chad Kawa, MD ... individuals in the local community. , Colon cancer is the second leading cause ... cancer while it is small, confined and easier to treat. If you are 50 ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash Association, the ... New York City-based sports and entertainment marketing firm Leverage Agency as its exclusive ... the Professional Squash Association (PSA), which includes first-time ever title sponsorship, naming rights, ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... HOUSTON , March 29, 2017  The leader ... announced that Drs. Sam Daher , Manal ... and David Couchat will be the featured microlecture ... the upcoming American Association of Orthodontists (AAO) Annual Session, ... to attend the microlectures beginning daily at 11:20 a.m. ...
(Date:3/29/2017)... ALBANY, New York , March 29, 2017 ... has recently published a report, which provides an ... According to the study, nearly 242 companies are ... highly fragmented and competitive. With the leading companies, ... and Purdue Pharma LP, focusing aggressively on various ...
(Date:3/29/2017)... 29, 2017 Varian Medical Systems (NYSE: ... the second quarter of fiscal year 2017 following the close ... release will be followed by a teleconference available to all ... a link to the conference call webcast will be available ... the teleconference call and replay: ...
Breaking Medicine Technology: